everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...1516171819202122232425...132133»
  • ||||||||||  verapamil / Generic mfg., everolimus / Generic mfg., cyclosporine / Generic mfg.
    REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME AND PRES POST-LIVER TRANSPLANT () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_1596;    
    She was initiated on verapamil with strict blood pressure control...Appropriate change in immunosuppressive regimen and strict BP control is critical for a successful outcome. This case highlights the challenges associated with diagnosis and management of PRES and RCVS post liver transplant.
  • ||||||||||  dexamethasone / Generic mfg., everolimus / Generic mfg.
    Journal:  Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). (Pubmed Central) -  Jan 25, 2023   
    There were no significant differences between groups seen in either of the coprimary endpoints; furthermore, we found no association between whole blood everolimus trough concentrations and toxicity. Although limited by poor enrollment, the results of this study do not suggest that prophylactic dexamethasone mouthwash is superior to therapeutic dexamethasone mouthwash (initiated at the first sign of mouth pain) for reducing the incidence or severity of mIAS from everolimus.
  • ||||||||||  Piqray (alpelisib) / Novartis
    Review, Journal:  Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. (Pubmed Central) -  Jan 22, 2023   
    This review aims to highlight the central role of PI3K-mTORC1/C2 mutations in the different BC subtypes, in terms of clinical outcomes and treatment efficacy. The broad base of knowledge in tumor biology is a key point for personalized BC therapy in the precision medicine era.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review. (Pubmed Central) -  Jan 14, 2023   
    Systemic therapy consists of everolimus, somatostatin analogs, peptide receptor radionuclide therapy, and chemotherapy...Despite lack of regulatory approvals for advanced disease, multiple options are available but should be sequenced according to the clinical status and disease biology. Each patient should be discussed in a multidisciplinary setting and clinical trials should be considered if available.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (clinicaltrials.gov) -  Jan 13, 2023   
    P1,  N=27, Completed, 
    Our study found limited treatment options upon relapse, demonstrating a need for further investigations into novel therapeutics and well-powered clinical trials to better inform on optimal treatments. Active, not recruiting --> Completed | Trial completion date: Jul 2022 --> Feb 2022 | Trial primary completion date: Jun 2022 --> Feb 2022
  • ||||||||||  everolimus / Generic mfg.
    Journal, Metastases:  Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. (Pubmed Central) -  Jan 12, 2023   
    Median PFS for sequential treatment with interferon-alpha (IFNa), everolimus and chemotherapy was 6, 5 and 9 months...However, efficacy of SSA but not PRRT was reduced at higher Ki-67 levels. SSA dose escalation provided limited disease stabilization.
  • ||||||||||  A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC). (On Demand | Level 1, West Hall; Poster Board No. N9) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_710;    
    P1
    In COSMIC-313, the triplet combination with cabozantinib (CABO)-ipilimumab (IPI)-nivolumab (NIVO) demonstrated promising efficacy compared to IPI-NIVO in pts with intermediate/poor risk disease, but definitive overall survival (OS) benefit has yet to be shown, and is associated with higher incidence of adverse events...Subsequent therapy is dependent on response, and can be NIVO 480mg IV Q4W (CR/PR/SD), lenvatinib 18mg + everolimus 5mg PO QD (PD on both prior regimens), or re-initiation of CABO 60mg PO QD (CR/PR/SD at CABO but PD on IPI-NIVO)...The trial is currently enrolling pts. Clinical trial information: NCT05188118.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Study of cabozantinib in second (On Demand | Level 1, West Hall; Poster Board No. N2) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_703;    
    P=N/A
    In the pivotal phase III METEOR study, cabozantinib demonstrated significantly improved progression-free survival (PFS), overall response rate (ORR) and overall survival (OS) versus everolimus in patients with previously treated aRCC with clear-cell component...Data collection started in Q3 2022 and the first patient was included on September 16th 2022. No interim analysis is planned.
  • ||||||||||  telaglenastat (CB-839) / Calithera
    Preclinical evaluation of teleglenastat (CB-839) in prostate cancer. (On Demand | Level 1, West Hall; Poster Board No. N16) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_435;    
    Additive or synergistic activity was difficult to assess with combination therapy since each drug was effective as monotherapy. Additional studies are needed to evaluate the role of EVE monotherapy or CB-839 + EVE in prostate cancer.
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Torisel (temsirolimus) / Pfizer
    Journal:  Why is rapamycin not a rapalog? (Pubmed Central) -  Jan 9, 2023   
    Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as 'rapalogs.' Rapamycin is the parent compound and should there with not be called a 'rapalog.'
  • ||||||||||  RSL3 / Stanford University
    Journal:  MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors. (Pubmed Central) -  Jan 6, 2023   
    Furthermore, we find that BON-1 and QGP-1 cells with MEN1 overexpression are more sensitive to everolimus, a widely used drug in pNETs that targets mTOR signaling. In addition, combined use everolimus with ferroptosis inducer, RSL3, possesses a more powerful ability to kill cells, which may provide a new strategy for the comprehensive therapy of pNETs.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. (Pubmed Central) -  Jan 3, 2023   
    Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection.
  • ||||||||||  Review, Journal:  Overview of therapeutic options for epilepsy. (Pubmed Central) -  Jan 1, 2023   
    (1) As first-line treatment, vigabatrin is unanimously recommended for infantile spasms and focal seizures before 2 years and is also widely used for seizures over 2 years, as are levetiracetam and carbamazepine. (2) If seizures persist (about 40% of children and adolescents), cannabidiol and everolimus, an inhibitor of the mTOR pathway, have recently been approved as adjunctive therapy to the arsenal of antiseizure medications authorized for this age group and to the ketogenic diet..
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex. (Pubmed Central) -  Jan 1, 2023   
    The issues of cost and access to affordable topical rapamycin formulations are critical for the patients even if skin changes do not cause serious harm in the context of TSC. We strongly suggest to improve and standardize the formulation of topical rapamycin, to encourage the pharmaceutical industry for providing commercial products, and the Health systems (social welfare) to reimburse them.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Malignant meningioma mTOR mutated and precision medicine. (Pubmed Central) -  Dec 26, 2022   
    This case report provides evidence on the efficacy of mTOR inhibitors as a treatment option in recurrent meningiomas. Furthermore, it highlights the importance of performing a molecular analysis as a preliminary step towards targeting the mTOR pathway.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Carcinoid tumors outside the abdomen. (Pubmed Central) -  Dec 24, 2022   
    In patients with refractory disease, therapy generally involves peptide receptor radioligand therapy, everolimus, or cytotoxic chemotherapy...Prognosis for both bronchial and thymic carcinoid tumors depends on histologic grade, local versus invasive disease, and extent of metastases. Herein we provide a summary of the pathophysiologic and clinical background, the current state of the field in diagnosis and management, and note of key ongoing prospective trials for patients with bronchial and thymic carcinoid tumors.